Please regularly visit the following Web sites and directly search for funding opportunities and deadlines in your research field.
Grants.gov: A central storehouse that lists all current funding opportunities from agencies of the United States government, including NIH, NSF, DOD, EPA, DOE, CDC, FDA, AHRQ, CMMS, and so on.
NIH Grants & Funding: A searchable database maintained by the NIH Office of Extramural Research on currently available biomedical research funding and training opportunities related to human health and diseases.
NSF Funding: The Foundation supports basic research and education in most fields, including biological, chemical, environmental, social, behavioral and economical sciences, collaborative research between universities and industry, and graduate and postdoctoral fellowships.
USDA NIFA Grants: Supports research and fellowships on nutrition and health, education, environment, biotechnology and genomics, economics and community development.
AHRQ Funding & Grants: Supports research to improve the quality, safety, efficiency, and effectiveness of healthcare for all Americans.
PCORI Funding: Funds research that will provide patients, their caregivers and clinicians with the evidence-based information needed to make better-informed healthcare decisions.
DOD Grants: Department of Defense Appropriations Act provides funding for many peer reviewed biomedical research programs managed by the Department of Defense (DOD) Office of Congressionally Directed Medical Research Programs (CDMRP). Such programs are usually announced between May and July for the following fiscal year.
DARPA (Defense Advanced Research Projects Agency): Funds research that investigates approaches advancing science, techonology, biology, engineering and computer sciences.
Proposal Central (Alzheimer’s Association, American Association for Cancer Research, Neilsen Foundation, Cystic Fibrosis Foundation, Epilepsy Foundation, Juvenile Diabetes Research Foundation, Lupus Foundation of America, Melanoma Research Foundation, Muscular Dystrophy Association, The Leukemia & Lymphoma Society, and others)
Agency for Healthcare Research & Quality (AHRQ)
American Asthma Foundation
American Diabetes Association
American Heart Association
American Institute for Cancer Research
American Lung Association
American Respiratory Care Foundation
Arthritis National Research Foundation
Cancer Research Institute
Human Frontier Science Program
Agency of Translational Health Sciences
National Foundation for Infectious Diseases
National Pharmaceutical Council
Susan G. Komen for the Cure
The Chronicle of Philanthropy
AACP regularly searches for other relevant research funding opportunities and makes them available below to our members.
Standard due dates for competing NIH applications
International Rett Syndrome Foundation Read-Through Program calls for potential pharmacological treatments that will bypass or read-through the MECP2 nonsense mutations to make a full-length functional MeCP2 protein. This program will serve 35% of girls with Rett syndrome. Investigators will use the ANGEL (Advanced Neurotherapeutic Grant of Excellence) grant mechanism to apply to this program. ANGEL grant awards must be comprised of very specific programs that are focused on pre-clinical drug discovery and development or clinical testing of therapeutic candidates, specifically those that target MECP2 nonsense mutations. April 1, 2015 deadline
PhRMA Foundation Pre-Doctoral Fellowships for Health Outcomes aim at supporting promising students during their thesis research. The program provides a stipend and funds to cover costs incidental to the training. The program assumes that the fellows will devote full-time (including summers) to their research. The PhRMA Foundation fellowship may not be used as a supplement to funds from other fellowships, traineeships or assistantships. The focus of the program is to assist in the pre doctoral training of the candidate. It should not be viewed as a program to fund a research project.
PhRMA Foundation Post-Doctoral Fellowships for Health Outcomes is to support postdoctoral career development activities of individuals prepared (or preparing) to engage in research that will strengthen representation of health outcomes in schools of pharmacy, medicine, nursing and public health.
PhRMA Foundation Research Starter Grants for Health Outcomes offer financial support to individuals beginning their independent research careers at the faculty level. This program supports individuals beginning independent research careers in academia who do not have other substantial sources of research funding. Health outcomes research spans a broad spectrum of issues from studies evaluating the effectiveness of a particular pharmaceutical intervention to the impact of reimbursement policies on the outcomes of care. It also ranges from the development and use of tools to perform patient-based assessments to analyses of the best way to disseminate the results of outcomes research to providers or consumers to encourage behavior change.
PhRMA Foundation Sabbatical Fellowships for Health Outcomes provide stipend support for individuals engaged in a multidisciplinary research training program that will create or extend their credentials in health outcomes. The purpose (intent) of this program is to enable faculty with active research programs to work outside of their home institution to learn new skills or develop new collaborations that will enhance their research and research training capabilities in health outcomes.
NIH Early-Stage Pharmacological Validation of Novel Targets and Accompanying Pre-Therapeutic Leads for Diseases of Interest to the NIDDK (R01) is to promote translation of basic science research into knowledge and tools that can be utilized to provide strong justification for later-phase drug discovery and development efforts in areas relevant to the National Institute of Diabetes and Digestive and Kidney Diseases. This includes obesity, diabetes and related aspects of endocrinology and metabolism, digestive diseases, liver diseases, nutrition, kidney and urological diseases, hematology, and specific aspects of cystic fibrosis. March 7, 2016 deadline
NIH Discovery of In Vivo Chemical Probes (R01) support investigators who have interest and capability to join efforts for the discovery of in vivo chemical probes. It is expected that applicants will have in hand the starting compounds ("validated hits") for chemical optimization and bioassays for testing new analog compounds. Through this FOA, NIH wishes to stimulate research in 1) discovery and development of novel, small molecules for their potential use in studying disease treatment relevant to the missions of the participating NIH Institutes, and 2) discovery and/or validation of novel, biological targets that will inform studies of disease mechanisms. Emphasis will be placed on projects that provide new insight into important disease targets and processes. September 8, 2016 deadline
NIH Blueprint Neurotherapeutics Network (BPN): Small Molecule Drug Discovery and Development for Disorders of the Nervous System (UH2/UH3) invites applications from neuroscience investigators seeking support to advance their small molecule drug discovery and development projects into the clinic. Participants in the BPN receive funding for activities to be conducted in their own laboratories and the opportunity to collaborate with NIH-funded consultants and contract research organizations (CROs) that specialize in medicinal chemistry, pharmacokinetics, toxicology, formulations development, chemical synthesis under Good Manufacturing Practices (GMP), and Phase I clinical testing. Projects can enter either at the Discovery stage, to optimize well-validated hit compounds through medicinal chemistry, or at the Development stage, to advance development candidates through Investigational New Drug (IND)-enabling toxicology studies and phase I clinical testing. Multiple deadline dates listed through 2017
NIH Strategic Alliances for Medications Development to Treat Substance Use Disorders (R01) supports research that advances compounds towards FDA approval by leveraging NIDA funds with the strengths and resources of outside organizations, such as for-profit and not-for-profit entities, including academic institutions, pharmaceutical and biotechnology companies, private and public foundations, and small businesses. Multiple deadline dates listed through 2017
DOE FY 2015 Continuation of Solicitation for the Office of Science Financial Assistance Program: Basic Energy Sciences (BES) - Chemical Sciences, Geosciences, and Biosciences - Catalysis Science The mission of the Basic Energy Sciences (BES) program is to support fundamental research to understand, predict, and ultimately control matter and energy at the electronic, atomic, and molecular levels in order to provide the foundations for new energy technologies and to support DOE missions in energy, environment, and national security. The portfolio supports work in the natural sciences by emphasizing fundamental research in materials sciences, chemistry, geosciences, and biosciences. BES-supported scientific facilities provide specialized instrumentation and expertise that enable scientists to carry out experiments not possible at individual laboratories. April 1, 2015 deadline
NIH NeuroNEXT Clinical Trials (U01) encourages applications for exploratory clinical trials of investigational agents (drugs, biologics, surgical therapies or devices) that may contribute to the justification for and provide the data required fordesigning a future trial, for biomarker validation studies, or for proof of mechanism clinical studies. Diseases chosen for study should be based on the NINDS' strategic plan and clinical research interests. Successful applicants will be given access to the NeuroNEXT infrastructure. Following peer review, NINDS will prioritize and order trials that are given access to the NeuroNEXT infrastructure. The NeuroNEXT Clinical Coordinating Center (CCC) will work with the successful applicant to efficiently implement the proposed study. The NeuroNEXT Data Coordinating Center (DCC) will provide statistical and data management support. The NeuroNEXT clinical sites will provide recruitment/retention support as well as on-site implementation of the clinical protocol. April 3, 2015 deadline
Worldwide Cancer Research Grants fund scientific research that may, in future, help reduce the incidence of cancer or improve cancer survival. The sponsor awards project grants to support basic or translational research into the causes, mechanisms, diagnosis, treatment or prevention of cancer. The PI must be employed at a recognized, non-profit academic research institution anywhere in the world. April 24, 2015 deadline
Wellcome Trust Biomedical Science: Strategic Awards and Initiatives - Strategic Awards: Ebola Trials Funding Call support research that can swiftly begin to investigate new approaches for preventing and treating the disease, during the current epidemic in West Africa. Its goals are to identify clinical interventions, including drugs and vaccines, with the potential to contribute to tackling the present crisis in Liberia, Sierra Leone, Guinea and Nigeria. Continuous applicationAccelerate Brain Cancer Cure - Brain Tumor Research Proposal funds projects at each stage of the drug development pipeline to ensure promising leads are advanced as quickly as possible. The pre-clinical screening program breaks down barriers to entry, academic grants focus on novel therapies, and industry investments bring the most promising treatments to patients quickly. Unspecified deadline
U.S. Army Medical Research and Materiel Command Broad Agency Announcement for Extramural Medical Research: Military Infectious Diseases Research Program focuses on vaccines, antiparasitic drugs, deployable field clinical diagnostics (human and vector), prophylactics and novel therapeutics to treat multi-drug resistant organisms in combat wound infections, and vector control - pertinent to naturally-occurring endemic diseases with demonstrated or potential capability to decrease military operational effectiveness. Diseases of principal interest to the MIDRP are malaria, dengue, diarrheal disease caused by bacteria, and norovirus. The MIDRP also has smaller research programs focused on cutaneous leishmaniasis, scrub typhus, adenovirus and hemorrhagic diseases not on the Defense Threat Reduction Agency (DTRA) biothreat list. Proposals/applications involving viral and bacterial biowarfare threats, chemical threats, and cancer research cannot be supported by the MIDRP. Continuous application
Michelson Grant in Reproductive Biology: The Michelson Grants is an international program open to any entity, including academic institutions, biotechnology firms, research institutes, and well-qualified individuals or groups. They encourage applications from scientists from a wide range of disciplines, including, but not limited to, biology, bioengineering, biotechnology, cell biology, endocrinology, gene silencing, immunology, materials science, nanotechnology, neuroscience, pharmacology, reproductive biology, and theriogenology. Continuous letter of intent submission
Last update 04/01/15 Next update 04/02/15
Kirsten F. Block, Ph.D.Associate Director of Research and Graduate Programs703-739-2330 ext. 1042